Pomerantz Files Securities Class Action Against Nektar Over REZOLVE‑AA Trial Disclosures
The filing sets a May 5 deadline for investors to seek a lead role in a case over alleged misstatements about a Phase 2b alopecia study.
Overview
- Pomerantz filed a securities class action in the Northern District of California, docket 26-cv-01951, seeking damages under Sections 10(b), 20(a), and Rule 10b-5.
- The complaint says Nektar told investors the Phase 2b REZOLVE-AA alopecia study followed enrollment rules when it did not.
- Nektar later said the trial missed statistical significance and pointed to four ineligible patients, and the stock fell 7.77% to $49.16 after that disclosure.
- The putative class covers buyers of Nektar shares from February 26 to December 15, 2025, who may seek appointment as lead plaintiff by May 5, 2026.
- Law firms including Rosen and Glancy are recruiting investors before the cutoff, and any lead plaintiff would direct the case on behalf of the class.